rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TNXP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      HHS Honors MyLymeData: How Data From 20,000 Patients Reveals the Dangers of Delayed Lyme Diagnosis
      Nov 17Yahoo FinanceTNXP
      Tonix Pharmaceuticals (TNXP) Stock Fair Value Falls As Analysts Weigh Tonmya And Funding Risk
      Nov 12Yahoo FinanceTNXP
      Tonix Pharmaceuticals’ TONMYA Sales Jump 37% as Insurance Coverage Expands
      Nov 11Yahoo FinanceTNXP
      Tonix Pharmaceuticals at guggenheim conference: launch gains traction
      Nov 10Investing.comTNXP
      Tonix Pharmaceuticals Holding Corp. Q3 2026 Earnings Call Summary
      Nov 9Yahoo FinanceTNXP
      Tonix Pharmaceuticals Holding Corp (TNXP) Q3 2026 Earnings Call Highlights: Tonmya Sales Surge ...
      Nov 9Yahoo FinanceTNXP
      What Tonix Pharmaceuticals (TNXP) Said on Its Q3 Earnings Call
      Nov 9Yahoo FinanceTNXP
      Tonix Q3 2026 slides: TONMYA sales up 37%, shares fall on loss
      Nov 9Investing.comTNXP
      Tonix Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 9BenzingaTNXP
      Tonix earnings missed by $0.46, revenue topped estimates
      Nov 9Investing.comTNXP
      Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights
      Nov 9Yahoo FinanceTNXP
      Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
      Nov 4Yahoo FinanceTNXP
      Tonix presents Phase 3 fibromyalgia drug data at pain congress
      Oct 27Investing.comTNXP
      Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
      Oct 27Yahoo FinanceTNXP
      Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
      Oct 26Yahoo FinanceTNXP
      A New Fibromyalgia Drug Deal Reaches 21 Million More Medicare Lives. Her Own Plan Could Still Decide What She Pays

      A new fibromyalgia drug just reached tens of millions of Medicare members, and patients are already assuming their costs are settled. One document their insurer controls will tell a very different story before open enrollment closes December 7.

      Oct 22Yahoo FinanceTNXP
      Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
      Oct 19Yahoo FinanceTNXP
      Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
      Oct 15Yahoo FinanceTNXP
      Tonix expands Medicare coverage for fibromyalgia drug TONMYA
      Sep 22Investing.comTNXP
      Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

      New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second

      Sep 22Yahoo FinanceTNXP
      Raymond James reiterates Strong Buy on Tonix Pharma stock at $27
      Sep 22Investing.comTNXPRJF
      Analysts Are Bullish on Top Healthcare Stocks: ALX Oncology Holdings (ALXO), Tonix Pharma (TNXP)

      Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailALXOTNXP
      Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Tonix Pharma (TNXP) and Solventum Corporation (SOLV)

      Detailed price information for Solventum Corporation (SOLV-N) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailTNXP
      Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

      Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and

      Sep 12Yahoo FinanceTNXP
      Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push
      Sep 10Investing.comTNXP
      Tonix Pharma Appoints New Chief Commercial Officer

      Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailTNXP
      Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

      Mr. Englese’s leadership of Tonix’s commercial organization since 2024 has included the go-to-market strategy and U.S. launch of TONMYA®, with growth across sales, managed care, and patient accessBERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately. Mr

      Sep 8Yahoo FinanceTNXP
      Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

      BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that the management team will participate in a fireside chat and 1x1s at Cantor’s 2026 Global Healthcare Conference, being held September 9-11, 2026, in New York. Cantor’s 2026 Global Healthcare ConferenceFireside ChatPresenter: Seth Lederman, M.D., President and Chief Executive Of

      Sep 2Yahoo FinanceTNXP
      TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

      By David Bautz, PhD NASDAQ: TNXP READ THE FULL TNXP RESEARCH REPORT Business Update $11.0 Million in Net Revenue for Tonmya® in 2Q26 Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is continuing the commercial launch of Tonmya® following its approval in August 2025 and commercial launch in November 2025. Sales metrics for the second quarter of 2026 continue to show substantial growth in

      Sep 2Yahoo FinanceTNXP
      Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock
      Aug 31Investing.comTNXP
      Tonix Pharmaceuticals director bagger buys $12,600 in stock
      Aug 24Investing.comTNXP

      This is the newest page. Registered accounts read further back.